The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effective of Yt90-Zevalin therapy in patients
with diffuse large B-cell lymphoma that have achieved at least an unconfirmed partial
remission after 6 cycles of CHOP therapy.